Polynucleotides Injectable Market | USD 605.1 Million by 2034
The polynucleotides injectable market size was exhibited at USD 147.0 million in 2024 and is projected to hit around USD 605.1 million by 2034, growing at a CAGR of 15.2% during the forecast period 2025 to 2034.
The U.S. polynucleotides injectable market size is evaluated at USD 1.51 billion in 2024 and is projected to be worth around USD 6.53 billion by 2034, growing at a CAGR of 15.8% from 2025 to 2034.
The polynucleotides injectable market in North America has been experiencing significant growth in recent years due to increasing demand for advanced therapies and the presence of essential players in the region. The market is primarily driven by advancements in gene therapy and RNA-based therapeutics, as well as the launch of innovative products. Critically, polynucleotide-based injectables have not received approval from the FDA, thereby, it is expected that the market growth and share of the region will remain at the lower end during the forecast period.
U.S. Polynucleotides Injectable Market Trends
The U.S. polynucleotide injectable market is highly dynamic. It is projected to grow substantially due to the increasing adoption of personalized medicines and the growing demand for targeted therapies. The U.S. has a well-established biopharmaceutical industry, with several companies investing heavily in research and development activities related to polynucleotide-based therapies. The increasing geriatric population, which is more susceptible to skin aging and skin conditions, is also a significant factor driving the demand for effective aesthetic solutions. However, low confidence in the product from doctors & practitioners is expected to hinder growth.
According to a leading dermatologist in the U.S., “I don't know when the FDA is going to ever approve milt-derived chemical compounds for human use in Americans. I would not consider using polynucleotides until I see more long-term safety and outcome data.”
Europe Polynucleotides Injectable Market Trends
The European polynucleotide injectable market is also experiencing significant growth due to an increasing patient population base, easier regulatory approvals, and diverse needs from medical tourists. For instance, more than 140 injectables are approved in Europe as opposed to 22 in the U.S. Furthermore, novel technology penetration for aesthetic intervention is critically higher in the country, which drives growth. Some of the key brands available in the region are Nucleofill, Pluryal Silk, Rejuran, and others.
The UK polynucleotide injectable market has grown over the forecast period. The increasing demand for rejuvenation solutions and easier regulatory approvals drive the market's growth. For instance, polynucleotide injectable treatments are typically administered in two to three sessions spaced 2-3 weeks apart. Moreover, Dr. Mohan emphasizes that three treatments over this timeframe provide optimal results, highlighting the scientific foundation of polynucleotides. With a proven safety profile and over 1.8 million successful applications in both medical and aesthetic fields, these treatments are gaining trust among practitioners and patients.
Asia Pacific Polynucleotides Injectable Market Trends
The Asia Pacific polynucleotide injectable market held the largest revenue share of 47.7% in 2024 as the region is witnessing several key trends, including the emergence of domestic players offering low-cost products to expand market access and affordability. There is a strong presence of domestic competitors and multinational corporations in the region, with domestic players gaining success by catering to country-specific preferences. Innovations and improvements to treatments and products entering the Asia Pacific market also support sales growth, such as the recent approval of novel polynucleotide injectable products.
China's polynucleotide injectable market is growing over the forecast period, driven by rising consumer interest in advanced aesthetic treatments and skin rejuvenation solutions. Growing minimally invasive procedures, increasing disposable income, and a growing middle-class population. In addition, the entry of innovative products and advancements in injectable technology enhance treatment efficacy and patient satisfaction. With a strong focus on aesthetics and beauty trends, China is emerging as a key player in the polynucleotides injectable industry.
The Korean polynucleotide injectable market is anticipated to grow over the forecast period and is one of the key markets for polynucleotide injectables. Growing demand for rejuvenation solutions and increased demand for polynucleotide injections by Korean dermatologists drive the market's growth. According to the Injectable Skin Boosters article published in November 2024, among 235 board-certified Korean dermatologists specializing in cosmetic treatments, 88% reported using polynucleotide (PN) injections in their practices. In a separate clinical trial, Korean women who received four intradermal PN injections spaced two weeks apart experienced notable improvements in skin texture, including reduced pore size, enhanced skin thickness and tone, and diminished wrinkles and sagging, all without any significant adverse effects.
Latin American Polynucleotide Injectable Market Trends
The Latin American polynucleotide injectable market is experiencing significant growth due to a rising patient population base, easier regulatory approvals, and strategic initiatives by key players. For instance, in March 2024, Croma-Pharma partnered with Megalabs to expand access to its high-performance aesthetic products across Latin America and the Caribbean. The agreement was finalized in March 2024 and includes the divestiture of Croma's Brazil affiliate. It also grants Megalabs distribution rights for hyaluronic acid fillers, polynucleotide injectables, skincare products, and future technologies.
Brazil polynucleotide injectable market is anticipated to grow over the forecast period, driven by rising demand for non-invasive aesthetic solutions and skin rejuvenation treatments. The country’s beauty and wellness industry continues expanding, and more consumers seek personalized cosmetic procedures. Brazil's well-established market for cosmetic dermatology and its growing middle class create a productive environment for adopting advanced treatments like polynucleotide injectables. This trend is driven by the growing preference for precise and efficient treatments that cater to a broad range of consumers.
MEA Polynucleotide Injectable Market Trends
The MEA polynucleotide injectable market held a significant market share in 2024. Countries such as the UAE and Saudi Arabia, with their high disposable incomes and strong interest in advanced aesthetic procedures, are leading the market. In addition, increasing awareness of the benefits of polynucleotide-based therapies contributes to its rising popularity across the region. The expanding healthcare and aesthetic sectors in the MEA are enabling the growth of this innovative treatment.
Saudi Arabia polynucleotide injectable market is witnessing significant growth, driven by an increasing demand for non-invasive cosmetic treatments. With a rising focus on enhancing skin quality and addressing signs of aging, more individuals opt for polynucleotide injectables due to their effectiveness in rejuvenating and improving skin health. The growing popularity of aesthetic procedures in the country, along with an increasing number of healthcare providers offering these advanced treatments, is contributing to the market’s growth.
| Report Coverage | Details |
| Market Size in 2025 | USD 169.34 Million |
| Market Size by 2034 | USD 605.1 Million |
| Growth Rate From 2025 to 2034 | CAGR of 15.2% |
| Base Year | 2024 |
| Forecast Period | 2025-2034 |
| Segments Covered | Application, End-use, Region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional scope | North America; Europe; Asia Pacific; Latin America; MEA |
| Key Companies Profiled | PHARMA RESEARCH; BIOPLUS CO. LTD.; LG Chem; AMEELA; Mastelli; Pluryal; Promoitalia Laboratories; Fox Pharma; BR Pharm; DermaFocus |
The eye segment held the largest revenue share of 63.9% in 2024, driven by the growing demand for non-invasive solutions to address various eye-related concerns. Polynucleotide injectable improve the appearance of fine lines, wrinkles, and skin laxity around the delicate eye area, which is often a key concern for aging individuals. For instance, a study published in the Journal of Cosmetic Dermatology found that polynucleotide injections significantly improved periorbital skin quality, including increased elasticity and reduced appearance of crow's feet, without the need for more invasive procedures.
The forehead segment is anticipated to register the fastest CAGR over the forecast period. The market is driven by the rising consumer preference for minimally invasive aesthetic treatments that can address the visible signs of aging and enhance overall facial aesthetics. For instance, a recent study published in the Journal of Cosmetic Dermatology found that patients who received polynucleotide injections in the forehead area experienced a significant improvement in skin texture, reduced appearance of wrinkles, and enhanced facial rejuvenation without the need for more invasive procedures, including neurotoxins or dermal fillers.
The MedSpas segment held the largest revenue share of 46.0% in 2024, driven by consumers' growing demand for non-invasive aesthetic treatments. Polynucleotides' unique properties, which enable them to stimulate collagen production, enhance skin texture, and diminish the appearance of fine lines and wrinkles, have made these injectable treatments a highly sought-after option among MedSpa clients seeking natural and long-lasting aesthetic improvements. For instance, an American Med Spa Association survey found 10,488 medical spas operating in the U.S. in 2023 as consumers increasingly sought these facilities to receive treatments such as polynucleotide injections.
The Aesthetic & Cosmetic Centers segment is expected to grow at a significant rate over the forecast period. This rapid growth is driven by the rising consumer demand for minimally invasive aesthetic treatments that deliver natural-looking, long-lasting results. Aesthetic & Cosmetic Centers offer a wide range of services, including polynucleotide injectables, which are gaining popularity for improving skin texture, elasticity, and overall appearance. For instance, Pulse Light Clinic stated that polynucleotide injections deeply hydrate the skin, improving elasticity and youthful appearance. They stimulate natural collagen production for long-lasting skin health.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the polynucleotides injectable market
By Application
By End-use
By Regional
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Application
1.2.2. End Use
1.2.3. Regional scope
1.2.4. Estimates and forecasts timeline.
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Application outlook
2.2.2. End Use outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Polynucleotides Injectable Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Technological advancements
3.2.1.2. Growing demand for skin rejuvenation
3.2.1.3. Shifting focus towards regenerative aesthetics
3.2.2. Market restraint analysis
3.2.2.1. Limited access to the treatments
3.3. Polynucleotides Injectable Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.2. PESTEL Analysis
Chapter 4. Polynucleotides Injectable Market: Application Estimates & Trend Analysis
4.1. Application Market Share, 2024 & 2034
4.2. Segment Dashboard
4.3. Global Polynucleotides Injectable Market by Application Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2034 for the following
4.4.1. Eyes
4.4.1.1. Eyes market estimates and forecasts 2021 to 2034 (USD Million)
4.4.2. Lips
4.4.2.1. Lips market estimates and forecasts 2021 to 2034 (USD Million)
4.4.3. Forehead
4.4.3.1. Forehead market estimates and forecasts 2021 to 2034 (USD Million)
4.4.4. Jawline & Cheekbones
4.4.4.1. Jawline & Cheekbones market estimates and forecasts 2021 to 2034 (USD Million)
4.4.5. Others
4.4.5.1. Others market estimates and forecasts 2021 to 2034 (USD Million)
Chapter 5. Polynucleotides Injectable Market: End Use Estimates & Trend Analysis
5.1. End Use Market Share, 2024 & 2034
5.2. Segment Dashboard
5.3. Global Polynucleotides Injectable Market by End Use Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2034 for the following
5.4.1. MedSpas
5.4.1.1. MedSpas market estimates and forecasts 2021 to 2034 (USD Million)
5.4.2. Aesthetic & Cosmetic Centers
5.4.2.1. Aesthetic & cosmetic centers market estimates and forecasts 2021 to 2034 (USD Million)
5.4.3. Hospitals
5.4.3.1. Hospitals market estimates and forecasts 2021 to 2034 (USD Million)
Chapter 6. Polynucleotides Injectable Market: Regional Estimates & Trend Analysis
6.1. Regional Market Share Analysis, 2024 & 2034
6.2. Regional Market Dashboard
6.3. Global Regional Market Snapshot
6.4. Market Size, & Forecasts Trend Analysis, 2021 to 2034:
6.5. North America
6.5.1. North America
6.5.2. U.S.
6.5.2.1. Key country dynamics
6.5.2.2. Regulatory framework
6.5.2.3. Competitive scenario
6.5.2.4. U.S. market estimates and forecasts 2021 to 2034 (USD Million)
6.5.3. Canada
6.5.3.1. Key country dynamics
6.5.3.2. Regulatory framework
6.5.3.3. Competitive scenario
6.5.3.4. Canada market estimates and forecasts 2021 to 2034 (USD Million)
6.5.4. Mexico
6.5.4.1. Key country dynamics
6.5.4.2. Regulatory framework
6.5.4.3. Competitive scenario
6.5.4.4. Mexico market estimates and forecasts 2021 to 2034 (USD Million)
6.6. Europe
6.6.1. Europe
6.6.2. UK
6.6.2.1. Key country dynamics
6.6.2.2. Regulatory framework
6.6.2.3. Competitive scenario
6.6.2.4. UK market estimates and forecasts 2021 to 2034 (USD Million)
6.6.3. Germany
6.6.3.1. Key country dynamics
6.6.3.2. Regulatory framework
6.6.3.3. Competitive scenario
6.6.3.4. Germany market estimates and forecasts 2021 to 2034 (USD Million)
6.6.4. France
6.6.4.1. Key country dynamics
6.6.4.2. Regulatory framework
6.6.4.3. Competitive scenario
6.6.4.4. France market estimates and forecasts 2021 to 2034 (USD Million)
6.6.5. Italy
6.6.5.1. Key country dynamics
6.6.5.2. Regulatory framework
6.6.5.3. Competitive scenario
6.6.5.4. Italy market estimates and forecasts 2021 to 2034 (USD Million)
6.6.6. Spain
6.6.6.1. Key country dynamics
6.6.6.2. Regulatory framework
6.6.6.3. Competitive scenario
6.6.6.4. Spain market estimates and forecasts 2021 to 2034 (USD Million)
6.6.7. Denmark
6.6.7.1. Key country dynamics
6.6.7.2. Regulatory framework
6.6.7.3. Competitive scenario
6.6.7.4. Denmark market estimates and forecasts 2021 to 2034 (USD Million)
6.6.8. Sweden
6.6.8.1. Key country dynamics
6.6.8.2. Regulatory framework
6.6.8.3. Competitive scenario
6.6.8.4. Sweden market estimates and forecasts 2021 to 2034 (USD Million)
6.6.9. Norway
6.6.9.1. Key country dynamics
6.6.9.2. Regulatory framework
6.6.9.3. Competitive scenario
6.6.9.4. Norway market estimates and forecasts 2021 to 2034 (USD Million)
6.7. Asia Pacific
6.7.1. Asia Pacific
6.7.2. Japan
6.7.2.1. Key country dynamics
6.7.2.2. Regulatory framework
6.7.2.3. Competitive scenario
6.7.2.4. Japan market estimates and forecasts 2021 to 2034 (USD Million)
6.7.3. China
6.7.3.1. Key country dynamics
6.7.3.2. Regulatory framework
6.7.3.3. Competitive scenario
6.7.3.4. China market estimates and forecasts 2021 to 2034 (USD Million)
6.7.4. India
6.7.4.1. Key country dynamics
6.7.4.2. Regulatory framework
6.7.4.3. Competitive scenario
6.7.4.4. India market estimates and forecasts 2021 to 2034 (USD Million)
6.7.5. Australia
6.7.5.1. Key country dynamics
6.7.5.2. Regulatory framework
6.7.5.3. Competitive scenario
6.7.5.4. Australia market estimates and forecasts 2021 to 2034 (USD Million)
6.7.6. South Korea
6.7.6.1. Key country dynamics
6.7.6.2. Regulatory framework
6.7.6.3. Competitive scenario
6.7.6.4. South Korea market estimates and forecasts 2021 to 2034 (USD Million)
6.7.7. Thailand
6.7.7.1. Key country dynamics
6.7.7.2. Regulatory framework
6.7.7.3. Competitive scenario
6.7.7.4. Thailand market estimates and forecasts 2021 to 2034 (USD Million)
6.8. Latin America
6.8.1. Latin America
6.8.2. Brazil
6.8.2.1. Key country dynamics
6.8.2.2. Regulatory framework
6.8.2.3. Competitive scenario
6.8.2.4. Brazil market estimates and forecasts 2021 to 2034 (USD Million)
6.8.3. Argentina
6.8.3.1. Key country dynamics
6.8.3.2. Regulatory framework
6.8.3.3. Competitive scenario
6.8.3.4. Argentina market estimates and forecasts 2021 to 2034 (USD Million)
6.9. MEA
6.9.1. MEA
6.9.2. South Africa
6.9.2.1. Key country dynamics
6.9.2.2. Regulatory framework
6.9.2.3. Competitive scenario
6.9.2.4. South Africa market estimates and forecasts 2021 to 2034 (USD Million)
6.9.3. Saudi Arabia
6.9.3.1. Key country dynamics
6.9.3.2. Regulatory framework
6.9.3.3. Competitive scenario
6.9.3.4. Saudi Arabia market estimates and forecasts 2021 to 2034 (USD Million)
6.9.4. UAE
6.9.4.1. Key country dynamics
6.9.4.2. Regulatory framework
6.9.4.3. Competitive scenario
6.9.4.4. UAE market estimates and forecasts 2021 to 2034 (USD Million)
6.9.5. Kuwait
6.9.5.1. Key country dynamics
6.9.5.2. Regulatory framework
6.9.5.3. Competitive scenario
6.9.5.4. Kuwait market estimates and forecasts 2021 to 2034 (USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.3. Vendor Landscape
7.3.1. List of key distributors and channel partners
7.3.2. Key customers
7.3.3. Key company market share analysis, 2024
7.3.4. PHARMA RESEARCH
7.3.4.1. Company overview
7.3.4.2. Financial performance
7.3.4.3. Others benchmarking
7.3.4.4. Strategic initiatives
7.3.5. BIOPLUS CO., LTD.
7.3.5.1. Company overview
7.3.5.2. Financial performance
7.3.5.3. Others benchmarking
7.3.5.4. Strategic initiatives
7.3.6. LG Chem
7.3.6.1. Company overview
7.3.6.2. Financial performance
7.3.6.3. Others benchmarking
7.3.6.4. Strategic initiatives
7.3.7. AMEELA
7.3.7.1. Company overview
7.3.7.2. Financial performance
7.3.7.3. Others benchmarking
7.3.7.4. Strategic Initiatives
7.3.8. Mastelli
7.3.8.1. Company overview
7.3.8.2. Financial performance
7.3.8.3. Others benchmarking
7.3.8.4. Strategic initiatives
7.3.9. Pluryal, Promoitalia Laboratories, Fox Pharma, BR Pharm, DermaFocus
7.3.9.1. Company overview
7.3.9.2. Financial performance
7.3.9.3. Others benchmarking
7.3.9.4. Strategic initiatives
7.3.10. Promoitalia Laboratories
7.3.10.1. Company overview
7.3.10.2. Financial performance
7.3.10.3. Others benchmarking
7.3.10.4. Strategic initiatives
7.3.11. Fox Pharma
7.3.11.1. Company overview
7.3.11.2. Financial performance
7.3.11.3. Others benchmarking
7.3.11.4. Strategic initiatives
7.3.12. BR Pharm
7.3.12.1. Company overview
7.3.12.2. Financial performance
7.3.12.3. Others benchmarking
7.3.12.4. Strategic initiatives
7.3.13. DermFocus
7.3.13.1. Company overview
7.3.13.2. Financial performance
7.3.13.3. Others benchmarking
7.3.13.4. Strategic initiatives
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers